The Chinese name of Sarilumab

Sarilumab is an injectable prescription drug called an interleukin-6 (IL-6) receptor blocker. Salirumab is used to treat adult patients with moderately to severely active rheumatoid arthritis (RA) who have been treated with at least one other medicine called a disease-modifying antirheumatic drug (DMARD) but who is not responding well or is intolerable. Polymyalgia rheumatica (PMR) occurs after corticosteroids have been used without success, or when the dose of corticosteroids is slowly reduced (tapered) into intolerance.

Salirumab is injected into the skin every two weeks and is available in prefilled pens or prefilled syringes in doses of 150 or 200 mg. The recommended dose is 200 mg. If necessary, the dose can be adjusted individually. Salirumab is a drug that affects the immune system. Salirumab can reduce the body's immune system's ability to fight infections, and some people have developed serious infections while taking it, including tuberculosis (TB), infections caused by bacteria, fungi, or viruses that can spread throughout the body and may cause death. Your doctor will recommend testing for TB before starting salivolumab, and you should be closely monitored for signs and symptoms of TB during treatment.

The patent drug of Salirumab is a new type of drug for treating diseases. It has not yet been marketed in China, so it has not been included in the scope of medical insurance. The Chinese name of Salirumab sold in China has not yet been determined. Salirumab The common dosage form of the original drug is injection, which has been marketed overseas. The European version of specifications200mg*2 bottles is priced around 17,500 per box (The price may fluctuate due to exchange rates). There are currently no generics of Salirumab produced in other countries.